LCMC3: Long-term disease-free and overall survival and their association with ctDNA after neoadjuvant atezolizumab for NSCLC Meeting Abstract
| Authors: | Owen, D. H.; Chaft, J. E.; Haura, E. B.; Toloza, E.; Waqar, S. N.; Patterson, G. A.; Finley, D.; Blasberg, J.; Raz, D.; Salgia, R.; Lee, J. M.; Bunn, P.; Wistuba, I.; Kwiatowski, D. J.; Hirsch, F. R.; Gopalakrishnan, A.; Batra, A.; Brandão, E.; Grindheim, J. M.; Nicholas, A.; Johnson, A.; Schulze, K.; Shum, E.; Nagasaka, M.; Gainor, J.; McNamee, C. J.; Johnson, B. E.; Kris, M. G.; Rusch, V. W.; Carbone, D. P. |
| Abstract Title: | LCMC3: Long-term disease-free and overall survival and their association with ctDNA after neoadjuvant atezolizumab for NSCLC |
| Meeting Title: | 2024 World Conference on Lung Cancer |
| Keywords: | neoadjuvant; atezolizumab; ctdna |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 19 |
| Issue: | 10 Suppl. |
| Meeting Dates: | 2024 Sep 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-10-01 |
| Start Page: | S119 |
| Language: | English |
| ACCESSION: | WOS:001337925600203 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jtho.2024.09.213 |
| Notes: | Meeting Abstract: MA15.09 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
